

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/091010 A1

- (51) **International Patent Classification:**
A61P 17/00 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/IB2021/060006
- (22) **International Filing Date:**
29 October 2021 (29.10.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/107,340 29 October 2020 (29.10.2020) US
- (71) **Applicant:** **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).
- (72) **Inventors:** **FERRERO, Enrico**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **JUNT, Tobias**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **KOLBINGER, Frank**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **KOVARIK, Jiri**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LOESCHE, Christian**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).
- (74) **Agent:** **SARAH THOMPSON**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** USE OF AN IL-18 ANTAGONIST FOR TREATING AND/OR PREVENTION OF ATOPIC DERMATITIS OR A RELATED CONDITION




Figure 6

(57) **Abstract:** The present invention relates to the treatment and/or prevention of atopic dermatitis or a related condition. More specifically, the invention relates to the administration of an IL-18 antagonist, e.g., an anti-IL-18 antibody or a fragment thereof, to treat or prevent atopic dermatitis or a related condition in a subject in need thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*